Performance of a semi-automated approach for risk estimation using a common data model for longitudinal healthcare databases

Statistical Methods in Medical Research

Volumn 22, Issue 1, 2013, Pages 97-112

  Van Le, Hoa ^a,b   Beach, Kathleen J ^b   Powell, Gregory ^b   Pattishall, Ed ^b   Ryan, Patrick ^a,b   Mera, Robertino M ^b  

^a IL   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

common data model; drug safety; observational database; pharmacovigilance; propensity score; risk estimation; safety signal

Indexed keywords

ARTICLE; COHORT ANALYSIS; COMMON DATA MODEL; CORRELATION COEFFICIENT; DATA BASE; DRUG EXPOSURE; DRUG SAFETY; DRUG UTILIZATION; ELECTRONIC MEDICAL RECORD; HEALTH CARE; ICD-9; KAPPA STATISTICS; OBSERVATIONAL STUDY; PRESCRIPTION; PROCEDURES, PARAMETERS AND DEVICES; RETROSPECTIVE STUDY;

AUTOMATION; COMPUTER SIMULATION; ELECTRONIC HEALTH RECORDS; RISK;

EID: 84874493871     PISSN: 09622802     EISSN: 14770334     Source Type: Journal    
DOI: 10.1177/0962280211403599     Document Type: Article

References (54)

1. Piazza-Hepp TD, Kennedy DL. Reporting of adverse events to MedWatch. Am J Health Syst Pharm. 1995 ; 52 (13). 1436-1439
2. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999 ; 281 (9). 824-829 (Pubitemid 29113743)
3. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005 ; 165 (12). 1363-1369 (Pubitemid 40973418)
4. Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. The FDA and drug safety. A proposal for sweeping changes. Arch Intern Med. 2006 ; 166: 1938-1942 (Pubitemid 44537173)
5. Chan KA, Hauben M. Signal detection in pharmacovigilance: empirical evaluation of data mining tools. Pharmacoepidemiol Drug Saf. 2005 ; 14 (9). 597-599 (Pubitemid 41358694)
6. Platt R, Madre L, Reynolds R, Tilson H. Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf. 2008 ; 17 (12). 1175-1182
7. Mann RD, Wilton LV, Pearce GL, Mackay FJ, Dunn NR. Prescription-event monitoring (PEM) in 1996 - a method of non-interventional observational cohort pharmacovigilance. Pharmacoepidemiol Drug Saf. 1997 ; 6 (S3). S5 - S11 (Pubitemid 27483534)
8. Psaty BM, Korn D. Congress responds to the IOM drug safety report-in full. JAMA. 2007 ; 298 (18). 2185-2187 (Pubitemid 350106657)
9. Food and Drug Administration Amendments Act of 2007, Public Law 110-85, § 905(a)(3)(B)(i)-(ii).
10. U.S. Food and Drug Administration. The Sentinel Initiative: National Strategy for Monitoring Medical Product Safety, http://www.fda.gov/oc/ initiatives/advance/reports/report0508.html (2008, accessed 1 October 2009).
11. Bright AR, Nelson RC. Automated support for pharmacovigilance: a proposed system. Pharmacoepidemiol Drug Saf. 2002 ; 11 (2). 121-125 (Pubitemid 34464332)
12. Common Data Model (CDM) Specification. Observational Medical Outcomes Partnership (OMOP) Research Lab; Working Document. Version 1.2. May 18, 2009 at http://omop.fnih.org/sites/default/files/ OMOP%20CDM%20Specifications%2022may2009-Post.pdf (2009, accessed 25 September 2010).
13. Pesquita C, Faria D, Falcão AO, Lord P, Couto FM. Semantic similarity in biomedical ontologies. PLoS Comput Biol. 2009 ; 5: 7-7
14. The Medical Dictionary for Regulatory Activities (MedDRA). http://www.meddramsso.com/index.asp (accessed 20 September 2010).
15. Systematized Nomenclature of Medicine-Clinical Terms (SNOMED). http://www.ihtsdo.org/snomed-ct/ (accessed 20 September 2010).
16. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983 ; 70 (1). 41-55
17. Mera MR, Beach JK, Powell EG, Pattishall NE. Semi-automated risk estimation using large databases: quinolones and Clostridium difficile associated diarrhea. Pharmacoepidemiol Drug Saf. 2010 ; 19: 610-617
18. Hochberg A. 'Risk Estimation Analytical Methods', ProSanos Corporation at http://www.prosanos.com/uploaded/RiskEstimationAnalyticalMethods.pdf (accessed 22 September 2010).
19. Brookhart MA, Schneeweiss S, Rothman K, Glynn RJ, Avorn J, Sturmer T. Variable selection in propensity score models. Am J Epidemiol. 2006 ; 163: 1149-1156 (Pubitemid 43987579)
20. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996 ; 49 (12). 1373-1379 (Pubitemid 27028925)
21. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007 ; 165 (6). 710-718 (Pubitemid 46348374)
22. Haerian H, McHugh P, Brown R, Somes G, Solomon SS. Gatifloxacin produces both hypoglycemia and hyperglycemia: a retrospective study. Am J Med Sci. 2008 ; 335 (2). 95-98 (Pubitemid 351253403)
23. Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin. 2005 ; 21 (5). 761-768 (Pubitemid 40695298)
24. McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf. 2006 ; 15 (7). 444-453 (Pubitemid 44150867)
25. Wang J, Mullins CD, Mamdani M, Rublee DA, Shaya FT. New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study. Ann Pharmacother. 2007 ; 41 (6). 937-943 (Pubitemid 46917619)
26. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005 ; 330 (7489). 445-445
27. L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol. 2004 ; 44 (1). 159-164 (Pubitemid 38976480)
28. Seeger JD, West WA, Fife D, Noel GJ, Johnson LN, Walker AM. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf. 2006 ; 15 (11). 784-792 (Pubitemid 44762709)
29. Cheng RM, Mamdani M, Jackevicius CA, Tu K. Association between ACE inhibitors and acute pancreatitis in the elderly. Ann Pharmacother. 2003 ; 37 (7-8). 994-998 (Pubitemid 36875227)
30. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum. 2006 ; 54 (5). 1435-1439
31. Ray WA, Daugherty JR, Griffin MR. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev. 2002 ; 8 (4). 276-279
32. Cadarette SM, Katz JN, Brookhart MA, Stürmer T, Stedman MR, Solomon DH. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med. 2008 ; 148 (9). 637-646 (Pubitemid 351669108)
33. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007 ; 356 (1). 29-38 (Pubitemid 46041751)
34. Johannes CB, Ziyadeh N, Seeger JD, Tucker E, Reiter C, Faich G. Incidence of allergic reactions associated with antibacterial use in a large, managed care organization. Drug Saf. 2007 ; 30 (8). 705-713 (Pubitemid 47295830)
35. Abraham NS, El-Serag HB, Hartman C, Richardson P, Deswal A. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther. 2007 ; 25 (8). 913-924 (Pubitemid 46525353)
36. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007 ; 57 (8). 1431-1438 (Pubitemid 350308841)
37. Duncan E, Dunlop BW, Boshoven W, Woolson SL, Hamer RM, Phillips LS. Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population. Int Clin Psychopharmacol. 2007 ; 22 (1). 1-11 (Pubitemid 44950762)
38. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007 ; 109 (2 Pt 1). 339-346 (Pubitemid 46197426)
39. Patterson MK, Castellsague J, Walker AM. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. Pharmacoepidemiol Drug Saf. 2008 ; 17 (10). 982-988
40. van Staa TP, Boulton F, Cooper C, Hagenbeek A, Inskip H, Leufkens HG. Neutropenia and agranulocytosis in England and Wales: incidence and risk factors. Am J Hematol. 2003 ; 72 (4). 248-254 (Pubitemid 36383975)
41. Meropol SB, Chan KA, Chen Z, et al. Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol Drug Saf. 2008 ; 17 (5). 523-532 (Pubitemid 351722040)
42. Moses LE, Mosteller F, Buehler JH. Comparing results of large clinical trials to those of meta-analyses. Stat Med. 2002 ; 21: 793-800 (Pubitemid 34211050)
43. Ioannidis JPA, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001 ; 286: 821-830 (Pubitemid 33015576)
44. Tannen RL, Weiner MG, Marcus SM. Simulation of the Syst-Eur randomized control trial using a primary care electronic medical record was feasible. J Clin Epidemiol. 2006 ; 59 (3). 254-264 (Pubitemid 43243651)
45. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977 ; 33: 159-174 (Pubitemid 8054849)
46. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics. 1977 ; 33: 363-374 (Pubitemid 8131514)
47. Barrett P. Assessing the reliability of rating data. Intraclass Correlation and Variance Component Methods. April 2 2007.
48. Poole C. Low P-values or narrow confidence intervals: which are more durable?. Epidemiology. 2001 ; 12 (3). 291-294 (Pubitemid 32336389)
49. Feinstein AR, Cicchetti DV. High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol. 1990 ; 43 (6). 543-549
50. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009 ; 20 (4). 512-522
51. i3 Aperio at http://www.i3global.com/Solutions/DrugSafety/i3Aperio/ (accessed 20 September 2010).
52. Fleiss JL The design and analysis of clinical experiments. New York: John Wiley & Sons ; 1986 :
53. Xie F, Li SC, Lo NN, Yeo SJ, Yang KY, Yeo W, et al. Cross-cultural adaptation and validation of Singapore English and Chinese Versions of the Oxford Knee Score (OKS) in knee osteoarthritis patients undergoing total knee replacement. Osteoarthritis Cartilage 2007; 15(9): 1019-24. Epub 2007 Apr 3. (Pubitemid 47387029)
54. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986 ; 73: 13-22